BDX Stock Forecast & Price Target

Becton Dickinson is well-positioned for growth, evidenced by its entry into a nearly $400 million biosurgery market that is projected to grow at approximately 5%, strengthening its overall market presence. The company anticipates positive volume growth in China, with management indicating that volume-based procurement will encompass around 80% of its portfolio by the end of 2026, further enhancing its growth prospects in the region. Additionally, BD Connected Care has demonstrated robust performance, achieving $1.13 billion in sales, a year-over-year increase of 4.7% excluding foreign exchange, alongside significant gains in competitive market share for its Alaris product.

Becton Dickinson faces a challenging financial landscape characterized by a projected decline in revenue growth, particularly within its newly structured business segments, which could hinder overall earnings per share (EPS) growth despite ongoing investments in innovation and commercial capabilities. The company's dependence on international markets, notably affected by market dynamics in China and lower funding for lifesciences research, adds additional pressure to its top-line performance. Coupled with expected margin headwinds from business investments and potential dilution effects from mergers and acquisitions, these factors contribute to a significantly negative outlook for the company’s stock in the near term.